A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- Registration Number
- NCT00225550
- Lead Sponsor
- Adherex Technologies, Inc.
- Brief Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Texas M.D. Anderson Cancer Center
🇺🇸Houston, Texas, United States
University of Texas M.D. Anderson Cancer Center🇺🇸Houston, Texas, United States